Current status of monoclonal antibodies for imaging and therapy of prostate cancer.
It is clear that there is significant need for improved staging and therapy of prostate cancer. The attributes and strengths of MoAbs seem particularly well-suited to the setting of prostate cancer. Recent progress in the application of MoAbs to in vivo imaging and therapy is encouraging. Clearly, further such efforts in prostate cancer are warranted.
Bander
N H
NH
Laboratory of Urological Oncology, New York Hospital-Cornell Medical Center, NY 10021.
D000911:Antibodies, Monoclonal; D006801:Humans; D000922:Immunotoxins; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016719:Radioimmunodetection; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000922:Immunotoxins